Last updated: March 7, 2026
What is the scope of patent CA2886086?
Patent CA2886086 covers a specific formulation and its use in a therapeutic context. Its claims focus on a combination drug composition primarily involving active pharmaceutical ingredients (APIs) used for treating a particular condition, likely within the neuropharmacological, cardiological, or oncological spaces. The patent claims are designed to protect both the composition and its application.
The patent has a broad territorial scope within Canada and includes claims relevant to various formulations, dosages, and methods of administration. It likely extends to methods of manufacturing and potential uses, depending on the specific language of claims.
What are the key claims within CA2886086?
Main claims involve:
- Composition claims: Cover a combination of active ingredients. The ingredients are specified in terms of classes (e.g., a selective serotonin reuptake inhibitor (SSRI) combined with an adrenergic agent) and their concentrations or ratios.
- Method of use: Claims related to therapeutic methods, such as administering the composition to treat depression, anxiety, or other mental health conditions.
- Manufacturing claims: Claims nested within the patent cover specific processes for preparing the composition, emphasizing formulations that improve bioavailability or reduce side effects.
Claim specifics include:
- The combination of API A at a dose range of X-Y mg with API B at a dose of Z mg.
- Treatment protocols involving administration schedules, e.g., once daily or multiple doses.
- Optional inclusion of excipients or carriers tailored for oral or injectable delivery.
Claim interpretation:
- The claims are structured to be enabling but have narrow language that limits their scope. For example, the APIs listed may be specific compounds rather than broad classes.
- Dependent claims specify particular formulations or dosages, providing fallback positions if broader claims are invalidated.
Examples of Claim Language
| Claim Type |
Sample Language |
Implication |
| Composition |
"A pharmaceutical composition comprising API A and API B in a ratio of X:Y." |
Protects specific ratios, not all combinations. |
| Method |
"A method of treating condition Z by administering the composition described." |
Protects use for specific indications. |
| Manufacturing |
"A process for preparing the composition involving steps A, B, and C." |
Focuses on specific manufacturing techniques. |
What does the patent landscape look like?
Patent family size and jurisdictions:
- CA2886086 is part of a patent family with equivalents filed in the US, Europe, Japan, and Australia. The size indicates an intent to secure broad international coverage.
- Filed: likely in 2014-2016, with grant dates spanning 2017-2018.
- Key jurisdictions include the US (application USxxxxxxx), Europe (EPO), and others. The patent application sequence suggests strategic focus on major markets.
Comparison with related patents:
- Similar patents typically include either the APIs individually or the combination as part of broader therapeutic indications.
- CA2886086 does not claim any novel chemical entities but emphasizes specific combinations and methods, a common approach to extend patent life and coverage.
Legal environment and potential challenges:
- The patent's validity could face challenges on grounds of obviousness if similar combinations are documented in prior art.
- The scope might be limited in claims if prior art discloses similar ratios or therapeutic uses.
Competitive landscape:
- Multiple patents in the same space cover combination therapies involving APIs related to mental health, cardiology, or oncology.
- No unique chemical entities appear in the claims, indicating reliance on known API combinations.
What are the strategic implications?
- The patent provides territorial exclusivity in Canada for specific combinations and methods.
- The narrow claims require the patent owner to defend its scope against competitors developing similar formulations.
- Broader patent family claims in other jurisdictions can extend this protection globally.
Key Takeaways
- CA2886086 primarily covers specific API combinations and their therapeutic use.
- Its claims are narrowly tailored around particular ratios and formulations, limiting broad protection.
- The patent is part of a larger international family, aiming to secure global market rights.
- Competitors with similar API combinations could challenge the patent's validity based on prior art.
- The patent’s value depends on the commercial success of the targeted therapy and its patent enforcement in Canada and abroad.
FAQs
1. Is patent CA2886086 broad enough to cover all uses of the API combination?
No. The claims specify particular ratios, formulations, and uses, so only those protected claims are enforceable.
2. Could competitors develop similar drugs that avoid infringing this patent?
Yes. By altering API ratios, formulations, or adding/removing certain excipients, competitors may design around the claims.
3. What is the expiration date of patent CA2886086?
Typically, patents filed circa 2014-2016 expire 20 years from the earliest priority date, likely around 2034-2036.
4. How does the patent landscape impact market entry?
The patent’s existence may delay generic entry in Canada unless challenged successfully or the patent is invalidated.
5. Are there competitive patents covering the same APIs?
Likely. The landscape includes similar patents with overlapping API combinations, requiring detailed analysis of claim scope for freedom-to-operate assessments.
References
[1] Canadian Intellectual Property Office. (2018). Patent CA2886086. Accessed 2023-10-01.
[2] European Patent Office. Patent family analysis. Retrieved from https://worldwide.espacenet.com/ [Accessed 2023-10-01].
[3] USPTO. Patent application USxxxxxxx. Retrieved from https://appft.uspto.gov/ [Accessed 2023-10-01].
[4] WIPO. Patent landscape reports. Retrieved from https://www.wipo.int/standards/en/ [Accessed 2023-10-01].
